Rare Genetic Disorders: Unraveling the Pathophysiology, Gene Mutations, and Therapeutic Advances in Fabry Disease and Marfan Syndrome

Fabry disease and Marfan syndrome are two distinct rare genetic disorders, each with intricate pathophysiologies, characterized by multi-organ involvement and life-threatening complications. This comprehensive review summarizes current knowledge on the pathophysiological mechanisms, gene mutations, and therapeutic approaches for these conditions. Fabry disease stems from mutations in the GLA gene, leading to deficient α-galactosidase A enzyme activity and subsequent accumulation of globotriaosylceramide (Gb3) in various tissues. This lipid storage disorder manifests with neuropathic pain, skin lesions, and progressive kidney and heart dysfunction. Early diagnosis through enzyme assays or genetic testing is vital. Enzyme replacement therapy (ERT) offers an effective therapeutic strategy, alleviating symptoms and slowing disease progression. Supportive care and personalized interventions are integral components of Fabry disease management. Marfan syndrome is primarily associated with mutations in the FBN1 gene, encoding truncated or nonfunctional fibrillin-1. Altered fibrillin-1 structure disrupts connective tissue homeostasis, resulting in diverse clinical manifestations. Pathophysiology encompasses skeletal abnormalities, ocular lens dislocation, and cardiovascular complications, notably aortic root dilation. The abstracted mutation of FBN1 necessitates a multidisciplinary approach to management, including regular aortic monitoring, lifestyle modifications, and emerging medical therapies. Understanding the pathophysiology and genetic basis of these two rare genetic disorders is paramount for timely diagnosis and effective management. While therapeutic options are available, ongoing research continues to refine treatments and holds promise for improving the quality of life for affected individuals. This review underscores the importance of a comprehensive approach, genetic counseling, and multidisciplinary care to optimize outcomes in these complex genetic disorders.